These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33275746)

  • 1. Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs.
    Engel ER; Walter JE
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):312-318. PubMed ID: 33275746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders.
    Malpica L; van Duin D; Moll S
    Am J Hematol; 2019 Dec; 94(12):1396-1412. PubMed ID: 31571266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
    Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
    Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
    Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
    J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis.
    Benamu E; Montoya JG
    Curr Opin Infect Dis; 2016 Aug; 29(4):319-29. PubMed ID: 27257797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
    Barmettler S; Ong MS; Farmer JR; Choi H; Walter J
    JAMA Netw Open; 2018 Nov; 1(7):e184169. PubMed ID: 30646343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with rituximab as an opportunity for the prevention of infectious complications].
    Polák P; Penka M; Smejkal P; Chlupová G
    Vnitr Lek; 2016; 62(5):398-405. PubMed ID: 27319233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
    JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
    McQuillen DP; Ram S
    Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab and immune deficiency: case series and review of the literature.
    Kaplan B; Kopyltsova Y; Khokhar A; Lam F; Bonagura V
    J Allergy Clin Immunol Pract; 2014; 2(5):594-600. PubMed ID: 25213054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.
    Bozio CH; Isenhour C; McNamara LA
    PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.
    Kim MS; Prasad V
    JAMA Intern Med; 2020 Feb; 180(2):315-317. PubMed ID: 31657842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
    Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
    J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.
    Szepanowski F; Warnke C; Meyer Zu Hörste G; Mausberg AK; Hartung HP; Kleinschnitz C; Stettner M
    CNS Drugs; 2021 Nov; 35(11):1173-1188. PubMed ID: 34657228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.